Toxicogenomics: an opportunity to optimise drug development and safety evaluation.
about
The role of investigative molecular toxicology in early stage drug development.New technologies and screening strategies for hepatotoxicity: use of in vitro models.Accelerating drug discovery.DNA damage and alterations in expression of DNA damage responsive genes induced by TiO2 nanoparticles in human hepatoma HepG2 cells.Pooling samples within microarray studies: a comparative analysis of rat liver transcription response to prototypical toxicants.
P2860
Toxicogenomics: an opportunity to optimise drug development and safety evaluation.
description
2002 nî lūn-bûn
@nan
2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
name
Toxicogenomics: an opportunity to optimise drug development and safety evaluation.
@ast
Toxicogenomics: an opportunity to optimise drug development and safety evaluation.
@en
type
label
Toxicogenomics: an opportunity to optimise drug development and safety evaluation.
@ast
Toxicogenomics: an opportunity to optimise drug development and safety evaluation.
@en
prefLabel
Toxicogenomics: an opportunity to optimise drug development and safety evaluation.
@ast
Toxicogenomics: an opportunity to optimise drug development and safety evaluation.
@en
P2860
P356
P1476
Toxicogenomics: an opportunity to optimise drug development and safety evaluation.
@en
P2093
Jeffrey A Kramer
Kyle L Kolaja
P2860
P304
P356
10.1517/14740338.1.3.275
P407
P577
2002-09-01T00:00:00Z